Despite the compensatory nature of BRG1/BRM in many tumorigenic contexts, concomitant loss of expression of the ATPases has been described in metastatic murine models and patient-derived non-small-cell lung cancer (NSCLC) cell lines and is associated with poor patient survival [90, 100, 101]. This evidence concerns the gene SMARCA2 and non-small cell lung carcinoma.